These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34038587)

  • 1. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
    Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
    J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma.
    Gorur A; Patiño M; Takahashi H; Corrales G; Pickering CR; Gleber-Netto FO; Myers JN; Cata JP
    Life Sci; 2021 Aug; 278():119541. PubMed ID: 33930368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.
    Singleton PA; Moreno-Vinasco L; Sammani S; Wanderling SL; Moss J; Garcia JG
    Am J Respir Cell Mol Biol; 2007 Aug; 37(2):222-31. PubMed ID: 17395891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
    Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
    J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.
    Mathew B; Lennon FE; Siegler J; Mirzapoiazova T; Mambetsariev N; Sammani S; Gerhold LM; LaRiviere PJ; Chen CT; Garcia JG; Salgia R; Moss J; Singleton PA
    Anesth Analg; 2011 Mar; 112(3):558-67. PubMed ID: 21156980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation.
    Singleton PA; Lingen MW; Fekete MJ; Garcia JG; Moss J
    Microvasc Res; 2006; 72(1-2):3-11. PubMed ID: 16820176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
    Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
    Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
    Wu TK; Ou YC; Chen YP; Huang FM; Pan YR; Lee CJ
    Anticancer Res; 2021 Aug; 41(8):3789-3799. PubMed ID: 34281838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.
    Wu X; Yeerna H; Goto Y; Ando T; Wu VH; Zhang X; Wang Z; Amornphimoltham P; Murphy AN; Tamayo P; Chen Q; Lippman SM; Gutkind JS
    Cancer Res; 2019 Sep; 79(17):4360-4370. PubMed ID: 31292160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
    Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
    Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of methylnaltrexone and naloxone on esophageal motor function in man.
    Scarpellini E; Pauwels A; Vos R; Rommel N; Tack J
    Neurogastroenterol Motil; 2017 Mar; 29(3):. PubMed ID: 28110513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.
    Janku F; Johnson LK; Karp DD; Atkins JT; Singleton PA; Moss J
    Ann Oncol; 2016 Nov; 27(11):2032-2038. PubMed ID: 27573565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Chen X; Cao Y; Sedhom W; Lu L; Liu Y; Wang H; Oka M; Bornstein S; Said S; Song J; Lu SL
    Mol Oncol; 2020 Jan; 14(1):139-158. PubMed ID: 31600013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma.
    Xu J; Lu W; Zhang S; Zhu C; Ren T; Zhu T; Zhao H; Liu Y; Su J
    Cancer Biol Ther; 2014 May; 15(5):612-22. PubMed ID: 24556606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.
    Sobral LM; Sousa LO; Coletta RD; Cabral H; Greene LJ; Tajara EH; Gutkind JS; Curti C; Leopoldino AM
    Mol Cancer; 2014 Feb; 13():32. PubMed ID: 24555657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis.
    Singleton PA; Garcia JG; Moss J
    Mol Cancer Ther; 2008 Jun; 7(6):1669-79. PubMed ID: 18566238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
    Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
    Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.
    Jiang Y; Cao W; Wu K; Qin X; Wang X; Li Y; Yu B; Zhang Z; Wang X; Yan M; Xu Q; Zhang J; Chen W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):365. PubMed ID: 31429766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.